Table 1.
Baseline Characteristics of Study Population
| Characteristic | All patients (N = 49,351) |
|---|---|
| Age, mean, yrs (SD) | 54.1 (12.3) |
| Age, yrs, N (%) | |
| 30–64 | 41,109 (83.3) |
| 65–74 | 4941 (10.0) |
| ≥75 | 3301 (6.7) |
| Sex, N (%) | |
| Female | 36,788 (74.5) |
| Male | 12,563 (25.5) |
| Urbanicity, N (%) | |
| Rural | 5690 (11.5) |
| Urban | 43,661 (88.5) |
| Region, N (%) | |
| Northeast | 8943 (18.1) |
| North Central | 12,156 (24.6) |
| South | 17,917 (36.3) |
| West | 9941 (20.1) |
| Unknown | 394 (0.8) |
| Plan type, N (%) | |
| EPO/PPO | 30,572 (61.9) |
| HMO | 6483 (13.1) |
| POS | 3074 (6.2) |
| Others | 7306 (14.8) |
| Missing/unknown | 1916 (3.9) |
| Payer type, N (%) | |
| Commercial | 41,570 (84.2) |
| Medicare | 7781 (15.8) |
| Formulation, N (%) | |
| Cleanser kit | 559 (1.1) |
| Cream | 10,908 (22.1) |
| Foam | 290 (0.6) |
| Gel | 34,720 (70.4) |
| Lotion | 2874 (5.8) |
| Therapy choice, N (%) | |
| Azelaic acid | 10,721 (21.7) |
| Benzoyl peroxide | 1084 (2.2) |
| Metronidazole | 35,868 (72.7) |
| Sodium sulfacetamide/sulfur | 1678 (3.4) |
EPO indicates exclusive provider organization; POS, point of service; PPO, preferred provider organization; SD, standard deviation.